Deleted Tweets From Scott Gottlieb, R-D.C.

RT @FDATobacco: FDA’s policy framework strikes a careful balance between making flavored tobacco products—especially e-cigs—less ac… https://t.co/GLLa1kkmQI

OMB Director Mick Mulvaney has been a principled partner to the #FDA and deeply public health minded in all his engagements with us; and we are absolutely delighted to have the opportunity to work with Mr. Mulvaney in this important new role. QT @MickMulvaneyOMB: This is a tremendous honor. I look forward to working with the President and the entire team. It’s going to be a gr… https://t.co/ee0Odre2Ma)

Follow me on Instagram at my new account ScottGottliebMD for updates on policy & public health https://t.co/W1zV6m58iN

RT @Surgeon_General: Law enforcement is crucial to fighting the opioid epidemic. #PAARISummit2018

RT @ivanoransky: Some personal career news: I'm thrilled to be joining the fantastic team at @Medscape. https://t.co/1TO6NklBXU

The new guidance also encourages sponsors to identify new biochemical or noninvasive imaging biomarkers that could eventually replace liver biopsies for monitoring progress and improvement, and that can be used for patient selection or for assessing efficacy in clinical trials.

Additional RWE use requires assessing RWD quality and our analytical methods. Claims data is structured with medical care info from many health systems. EHRs provide a wider range of info - lab results, imaging and clinical assessments but are often unstructured and inconsistent.

A naval aviator and war hero who rose to the highest level of leadership during times of geopolitical strife and ended the Cold War. A patriarch of an extraordinary family. A family many. George H. W. Bush will be remembered fondly by a half century of history that he shaped. https://t.co/hEPgyp9S9S

As part of FDA’s ongoing commitment to address the opioid crisis, the device center launched an Innovation Challenge in May 2018 to spur development of medical devices that could provide new solutions to addressing pain. Today we selected 8 submissions: https://t.co/lazjpqbo0s

RT @NCIDirector: Please vaccinate your children. @SGottliebFDA said it best: " The author captures exactly the risk and anguish accompanyin… QT @SteamLaundry: Dear parents of children who do not have cancer: a casual measles exposure in a grocery store caused the following… https://t.co/JLVWyLmGaa)

#FDA is taking new steps to address the challenges associated with the persistent shortages we've seen of critical drugs, especially when it comes to old, generic sterile drugs: https://t.co/lk9TyzNNlh

RT @RAPSorg: .@FDACDRHindustry’s Case for Quality Pilot Gains Momentum | #Regulatory Focus https://t.co/2FYIXirfSd #FDA #quality #manufacturing

Certain uses of science should be intolerable, and should cause scientists to be cast out. The use of CRISPR to edit human germ line cells should fall into that bucket. Anything less puts the beneficial uses of science and the entire enterprise at risk. https://t.co/OPE7r91ADY

RT @SGottliebFDA: Assuring the safety of medical products is central to FDA’s consumer protection mission. In today’s #FDA… https://t.co/gvjlmIXQTG

RT @SGottliebFDA: And this week, we’ll announce our intent to pursue the most significant modernization of the 510(k) clearance pathw… https://t.co/nSVPreZKKC

We'll have updates on our progress in these areas soon. We'll advance other new policies. Taking these and other new steps will enable us to make decisions about devices based on the best available evidence and allow us to continue to improve patients' health and safety. https://t.co/P12S2SYPPc

This year #FDA will receive 250 applications to start human studies with novel cell and gene therapies; about 100 will be for gene therapies. By 2021 we expect the annual total to reach 1,000. These fields are exploding; and hold tremendous promise for advancing public health. https://t.co/6AXr51ARO0

RT @FDAfood: Consumers should avoid all products containing tianeptine, especially those claiming to treat opioid use disorder.… https://t.co/AEb7uGA13P

RT @SGottliebFDA: My deep concern about youth e-cig use, and my goal of advancing innovations to help adult smokers quit, stems from… https://t.co/NJTLm8Fksw

RT @SGottliebFDA: My deep concern about youth e-cig use, and my goal of advancing innovations to help adult smokers quit, stems from… https://t.co/NJTLm8Fksw

RT @FDATobacco: FDA’s policy framework strikes a careful balance between making flavored tobacco products—especially e-cigs—less ac… https://t.co/GLLa1kkmQI

OMB Director Mick Mulvaney has been a principled partner to the #FDA and deeply public health minded in all his engagements with us; and we are absolutely delighted to have the opportunity to work with Mr. Mulvaney in this important new role. QT @MickMulvaneyOMB: This is a tremendous honor. I look forward to working with the President and the entire team. It’s going to be a gr… https://t.co/ee0Odre2Ma)

Follow me on Instagram at my new account ScottGottliebMD for updates on policy & public health https://t.co/W1zV6m58iN

RT @Surgeon_General: Law enforcement is crucial to fighting the opioid epidemic. #PAARISummit2018

RT @ivanoransky: Some personal career news: I'm thrilled to be joining the fantastic team at @Medscape. https://t.co/1TO6NklBXU

The new guidance also encourages sponsors to identify new biochemical or noninvasive imaging biomarkers that could eventually replace liver biopsies for monitoring progress and improvement, and that can be used for patient selection or for assessing efficacy in clinical trials.

Additional RWE use requires assessing RWD quality and our analytical methods. Claims data is structured with medical care info from many health systems. EHRs provide a wider range of info - lab results, imaging and clinical assessments but are often unstructured and inconsistent.

A naval aviator and war hero who rose to the highest level of leadership during times of geopolitical strife and ended the Cold War. A patriarch of an extraordinary family. A family many. George H. W. Bush will be remembered fondly by a half century of history that he shaped. https://t.co/hEPgyp9S9S

As part of FDA’s ongoing commitment to address the opioid crisis, the device center launched an Innovation Challenge in May 2018 to spur development of medical devices that could provide new solutions to addressing pain. Today we selected 8 submissions: https://t.co/lazjpqbo0s

RT @NCIDirector: Please vaccinate your children. @SGottliebFDA said it best: " The author captures exactly the risk and anguish accompanyin… QT @SteamLaundry: Dear parents of children who do not have cancer: a casual measles exposure in a grocery store caused the following… https://t.co/JLVWyLmGaa)

#FDA is taking new steps to address the challenges associated with the persistent shortages we've seen of critical drugs, especially when it comes to old, generic sterile drugs: https://t.co/lk9TyzNNlh

RT @RAPSorg: .@FDACDRHindustry’s Case for Quality Pilot Gains Momentum | #Regulatory Focus https://t.co/2FYIXirfSd #FDA #quality #manufacturing

Certain uses of science should be intolerable, and should cause scientists to be cast out. The use of CRISPR to edit human germ line cells should fall into that bucket. Anything less puts the beneficial uses of science and the entire enterprise at risk. https://t.co/OPE7r91ADY

RT @SGottliebFDA: Assuring the safety of medical products is central to FDA’s consumer protection mission. In today’s #FDA… https://t.co/gvjlmIXQTG

RT @SGottliebFDA: And this week, we’ll announce our intent to pursue the most significant modernization of the 510(k) clearance pathw… https://t.co/nSVPreZKKC

We'll have updates on our progress in these areas soon. We'll advance other new policies. Taking these and other new steps will enable us to make decisions about devices based on the best available evidence and allow us to continue to improve patients' health and safety. https://t.co/P12S2SYPPc

This year #FDA will receive 250 applications to start human studies with novel cell and gene therapies; about 100 will be for gene therapies. By 2021 we expect the annual total to reach 1,000. These fields are exploding; and hold tremendous promise for advancing public health. https://t.co/6AXr51ARO0

RT @FDAfood: Consumers should avoid all products containing tianeptine, especially those claiming to treat opioid use disorder.… https://t.co/AEb7uGA13P

RT @SGottliebFDA: My deep concern about youth e-cig use, and my goal of advancing innovations to help adult smokers quit, stems from… https://t.co/NJTLm8Fksw

RT @SGottliebFDA: My deep concern about youth e-cig use, and my goal of advancing innovations to help adult smokers quit, stems from… https://t.co/NJTLm8Fksw